Drugs / ORDESEKIMAB
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials · 4 missed | ||||||
| Phase 2 | NCT04338581 | Dec 2020 → Oct 2024 | vitiligo | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT04424927 | Aug 2020 → Jul 2024 | celiac disease | Provention Bio, a Sanofi Company | Completed | Missed primary |
| Phase 2 | NCT02637141 | Apr 2016 → Feb 2017 | celiac disease | Amgen | Completed | Missed primary |
| Phase 2 | NCT02633020 | Apr 2016 → Apr 2017 | refractory celiac disease, small intestine lymphoma | Amgen | Completed | Missed primary |
| Phase 2 | NCT00443326 | Mar 2007 → Dec 2008 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00433875 | Dec 2002 → ? | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT03439475 Background | — | celiac disease | Amgen | No longer available | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORDESEKIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109467 ↗ |
| Known as | AMG 714 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02633020 ↗ |
| Known as | HuMax-IL-15 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109467 ↗ |
| Known as | MAb146B7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109467 ↗ |
| Known as | PRV-015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04424927 ↗ |
| Action | Inhibit | “AMG 714, an anti-IL-15 monoclonal antibody” PMID 31494097 ↗ Sep 2019 |
| Modality | Monoclonal antibody | “Anti-IL 15 Human Monoclonal Antibody (AMG 714)” NCT00433875 ↗ |
| Route | Intravenous | “Patients were randomly assigned at a 2:1 ratio to receive seven intravenous doses over 10 weeks of AMG 714 (8 mg/kg) or matching placebo.” PMID 31494097 ↗ Sep 2019 |
| Target | IL15 | “AMG 714, an anti-IL-15 monoclonal antibody” PMID 31494097 ↗ Sep 2019 |